Allogeneic hematopoietic cell transplantation: from experimental biology to clinical care

[1]  J. Radich,et al.  HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  Y. Kwong.  Arsenic trioxide in the treatment of haematological malignancies , 2004, Expert opinion on drug safety.

[3]  C. Flowers,et al.  Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. , 2004, Blood.

[4]  C. Flowers,et al.  Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. , 2004, Blood.

[5]  A. Barrett,et al.  Review Articles (434 articles) , 2003 .

[6]  D. Blaise,et al.  Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. , 2004, Blood.

[7]  R. Storb,et al.  Hematopoietic cell transplantation: five decades of progress. , 2003, Archives of medical research.

[8]  R. Storb,et al.  Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. , 2003, Blood.

[9]  S. Heimfeld,et al.  HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. , 2003, Blood.

[10]  R. Storb,et al.  Postgrafting immunosuppression with sirolimus and cyclosporine facilitates stable mixed hematopoietic chimerism in dogs given sublethal total body irradiation before marrow transplantation from DLA-identical littermates. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  M. Maris,et al.  Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. , 2003, Blood.

[12]  S. Mackinnon,et al.  Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. , 2003, Blood.

[13]  M. Brechbiel,et al.  Selective T-cell ablation with bismuth-213–labeled anti-TCRαβ as nonmyeloablative conditioning for allogeneic canine marrow transplantation , 2003 .

[14]  C. Hurley,et al.  Maximizing optimal hematopoietic stem cell donor selection from registries of unrelated adult volunteers. , 2003, Tissue antigens.

[15]  Els Goulmy,et al.  Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R. Storb,et al.  Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissio , 2003, Blood.

[17]  M. Maris,et al.  Non‐myeloablative allografting from human leucocyte antigen‐identical sibling donors for treatment of acute myeloid leukaemia in first complete remission , 2003, British journal of haematology.

[18]  M. Maris,et al.  The transplantation of hematopoietic stem cells after non-myeloablative conditioning , 2003, Immunologic research.

[19]  R. Storb.  Allogeneic hematopoietic stem cell transplantation--yesterday, today, and tomorrow. , 2003, Experimental hematology.

[20]  J. Bourhis,et al.  Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. , 2002, Blood.

[21]  M. Maris,et al.  Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  J Wagner,et al.  Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. , 2002, Blood.

[23]  T. Panzarella,et al.  A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. , 2002, Blood.

[24]  R. Storb,et al.  Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. , 2002, Blood.

[25]  M. Maris,et al.  Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. , 2002, Blood.

[26]  H. Deeg,et al.  Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. , 2001, Blood.

[27]  R. Storb,et al.  Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. , 2001, Blood.

[28]  R. Storb,et al.  Nonmyeloablative hematopoietic cell transplant for treatment of immune deficiency , 2001, Current opinion in pediatrics.

[29]  R. Storb,et al.  Effects of extending the duration of postgrafting immunosuppression and substituting granulocyte-colony-stimulating factor-mobilized peripheral blood mononuclear cells for marrow in allogeneic engraftment in a nonmyeloablative canine transplantation model. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[30]  M. Maris,et al.  Non-myeloablative hematopoietic stem cell transplantation. , 2001, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

[31]  J. Radich,et al.  Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. , 2001, Blood.

[32]  R Storb,et al.  Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. , 2001, The New England journal of medicine.

[33]  D. Niederwieser,et al.  NONMYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTS (HSCT) FROM HLA-MATCHED RELATED DONORS FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES: CLINICAL RESULTS OF A TBI-BASED CONDITIONING REGIMEN , 2001 .

[34]  M. Maris,et al.  Nonmyeloablative hematopoietic stem cell transplantation , 2001 .

[35]  H. Deeg,et al.  Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[36]  J. Fay,et al.  Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. , 2000, Blood.

[37]  W. Linehan,et al.  Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. , 2000, The New England journal of medicine.

[38]  R. Collins,et al.  Donor leukocyte infusions in acute lymphocytic leukemia , 2000, Bone Marrow Transplantation.

[39]  S. Saidman,et al.  Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[40]  Y. Beguin,et al.  Adoptive immunotherapy with donor lymphocyte infusionsafter allogeneic HPC transplantation , 2000, Transfusion.

[41]  R. Storb,et al.  Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during chronic phase of chronic myeloid leukemia. , 1999, Blood.

[42]  N. Young,et al.  Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. , 1999, Blood.

[43]  H. Deeg,et al.  Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant. , 1999, Blood.

[44]  H. Deeg,et al.  Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation. , 1999, Blood.

[45]  S. Saidman,et al.  Mixed lymphohaemopoietic chimerism and graft-ver suslymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation , 1999, The Lancet.

[46]  M. Martelli,et al.  Improved outcome with T-cell-depleted bone marrow transplantation for acute leukemia. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  R. Naumann,et al.  Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. , 1999, Transplantation.

[48]  F. Aranha,et al.  A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies , 1998, Bone Marrow Transplantation.

[49]  J. Adamson,et al.  Outcomes among 562 recipients of placental-blood transplants from unrelated donors. , 1998, The New England journal of medicine.

[50]  M. Martelli,et al.  Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. , 1998, The New England journal of medicine.

[51]  A. Nademanee,et al.  Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. , 1998, Blood.

[52]  N. Ueno,et al.  Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  N. Schmitz,et al.  Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation , 1998, Bone Marrow Transplantation.

[54]  C Anasetti,et al.  Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. , 1998, The New England journal of medicine.

[55]  H. Deeg,et al.  Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. , 1998, Blood.

[56]  E. Warren,et al.  Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. , 1998, Blood.

[57]  A. Nagler,et al.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.

[58]  S. Mackinnon,et al.  T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. , 1998, Blood.

[59]  E. Estey,et al.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. , 1997, Blood.

[60]  E. Goulmy.  Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy , 1997, Immunological reviews.

[61]  H. Deeg,et al.  Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. , 1997, Blood.

[62]  J. Kurtzberg,et al.  Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. , 1996, The New England journal of medicine.

[63]  A. Nagler,et al.  Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. , 1995, Experimental hematology.

[64]  A Ferrant,et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.

[65]  S. Mackinnon,et al.  Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. , 1995, Blood.

[66]  H. Deeg,et al.  Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. , 1994, Blood.

[67]  H. Deeg,et al.  Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. , 1994, Blood.

[68]  A. Rimm,et al.  Identical-Twin Bone Marrow Transplants for Leukemia , 1994, Annals of Internal Medicine.

[69]  H. Deeg,et al.  FK‐506 AND METHOTREXATE PREVENT GRAFT‐VERSUS-HOST DISEASE IN DOGS GIVEN 9.2 Gy TOTAL BODY IRRADIATION AND MARROW GRAFTS FROM UNRELATED DOG LEUKOCYTE ANTIGEN‐NONIDENTICAL DONORS , 1993, Transplantation.

[70]  A. Rimm,et al.  T-cell depletion of HLA-identical transplants in leukemia. , 1991, Blood.

[71]  F. Appelbaum,et al.  Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. , 1991, Blood.

[72]  W. Wilmanns,et al.  Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. , 1990, Blood.

[73]  R. Hoffmann,et al.  Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. , 1988 .

[74]  J. Carbillet,et al.  T cell-depleted allogeneic bone marrow transplantation in a case of childhood idiopathic myelofibrosis. , 1987, Bone marrow transplantation.

[75]  D. Blaise,et al.  IMPACT OF T-CELL DEPLETION ON OUTCOME OF ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR STANDARD-RISK LEUKAEMIAS , 1987, The Lancet.

[76]  H. Deeg,et al.  Marrow transplantation for acute nonlymphoblastic leukemia in first remission: toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation. , 1986, Bone marrow transplantation.

[77]  H. Deeg,et al.  Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. , 1986, Blood.

[78]  H. Deeg,et al.  Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. , 1986, The New England journal of medicine.

[79]  H. Deeg,et al.  Marrow transplantation for the treatment of chronic myelogenous leukemia. , 1986, Annals of internal medicine.

[80]  R. Marcus,et al.  Bone marrow transplantation for patients with chronic myeloid leukemia. , 1986, The New England journal of medicine.

[81]  H. Deeg,et al.  Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. , 1985, Blood.

[82]  K. Sullivan,et al.  Allogeneic marrow transplantation. , 1984, Cancer investigation.

[83]  R. Brookmeyer,et al.  Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. , 1983, The New England journal of medicine.

[84]  K. Sullivan,et al.  Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. , 1983, The New England journal of medicine.

[85]  Wayne,et al.  Bone marrow ablation followed by allogeneic marrow grafting during first complete remission of acute nonlymphocytic leukemia. , 1983, Blood.

[86]  H. Deeg,et al.  CYCLOSPORIN A AND METHOTREXATE IN CANINE MARROW TRANSPLANTATION: ENGRAFTMENT, GRAFT‐VERSUS-HOST DISEASE, AND INDUCTION OF TOLERANCE , 1982, Transplantation.

[87]  R. Storb,et al.  Marrow transplantation for acute nonlymphoblastic leukemic in first remission using fractionated or single-dose irradiation. , 1982, International journal of radiation oncology, biology, physics.

[88]  K. Sullivan,et al.  Allogeneic marrow transplantation using fractionated total body irradiation in patients with acute lymphoblastic leukemia in relapse. , 1982, Leukemia research.

[89]  H. Deeg,et al.  High-dose total-body irradiation and autologous marrow reconstitution in dogs: dose-rate-related acute toxicity and fractionation-dependent long-term survival. , 1981, Radiation research.

[90]  K. Sullivan,et al.  Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. , 1981, The New England journal of medicine.

[91]  E. Scott,et al.  Bone-marrow ablation and allogeneic marrow transplantation in acute leukemia. , 1980, The New England journal of medicine.

[92]  P. Neiman,et al.  Marrow transplantation for acute nonlymphoblastic leukemia in first remission. , 1979, The New England journal of medicine.

[93]  R. Storb,et al.  Marrow transplantation for patients with acute lymphoblastic leukemia in remission. , 1979, Blood.

[94]  R. Storb,et al.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. , 1979, The New England journal of medicine.

[95]  P. Neiman,et al.  One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. , 1977, Blood.

[96]  R. Storb,et al.  Treatment of aplastic anemia by marrow transplantation from HLA identical siblings. Prognostic factors associated with graft versus host disease and survival. , 1977, The Journal of clinical investigation.

[97]  E Niskanen,et al.  MARROW TRANSPLANTATION , 1977, Duodecim; laaketieteellinen aikakauskirja.

[98]  R Storb,et al.  Bone-marrow transplantation (first of two parts). , 1975, The New England journal of medicine.

[99]  S. Agarwal,et al.  Letter: Alpha-fetoprotein in Indian childhood cirrhosis. , 1974, Lancet.

[100]  P. Neiman,et al.  Allogeneic marrow grafting for treatment of aplastic anemia. , 1974, Blood.

[101]  M. Bortin.  A COMPENDIUM OF REPORTED HUMAN BONE MARROW TRANSPLANTS , 1970, Transplantation.

[102]  R. Storb,et al.  METHOTREXATE REGIMENS FOR CONTROL OF GRAFT-VERSUS-HOST DISEASE IN DOGS WITH ALLOGENEIC MARROW GRAFTS , 1970, Transplantation.

[103]  G. Mathé,et al.  Adoptive immunotherapy of acute leukemia: experimental and clinical results. , 1965, Cancer research.

[104]  A. Levy,et al.  Prevention of Delayed Foreign Marrow Reaction in Lethally Irradiated Mice by Early Administration of Methotrexate , 1962, Nature.

[105]  J. Burchenal,et al.  Effect of total-body irradiation on the transplantability of mouse leukemias. , 1960, Cancer research.

[106]  D. Uphoff.  Alteration of Homograft Reaction by A-methopterin in Lethally Irradiated Mice Treated with Homologous Marrow , 1958, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[107]  J. Loutit,et al.  Treatment of Murine Leukaemia with X‐Rays and Homologous Bone Marrow: II , 1957, British journal of haematology.

[108]  J. Loutit,et al.  Treatment of Murine Leukaemia with X Rays and Homologous Bone Marrow , 1956, British medical journal.

[109]  T. Makinodan.  Circulating Rat Cells in Lethally Irradiated Mice Protected with Rat Bone Marrow.∗ , 1956, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[110]  C. E. Ford,et al.  Cytological Identification of Radiation-Chimæras , 1956, Nature.

[111]  P. Nowell,et al.  Growth and continued function of rat marrow cells in x-radiated mice. , 1956, Cancer research.

[112]  D. V. van Bekkum,et al.  Evidence for the cellular hypothesis in radiation protection by bone marrow cells. , 1956, Acta physiologica et pharmacologica Neerlandica.

[113]  R. Prehn,et al.  Successful skin homografts after the administration of high dosage X radiation and homologous bone marrow. , 1955, Journal of the National Cancer Institute.

[114]  E. Shelton,et al.  Modification of irradiation injury in mice and guinea pigs by bone marrow injections. , 1951, Journal of the National Cancer Institute.

[115]  L. Jacobson,et al.  EFFECT OF SPLEEN PROTECTION ON MORTALITY FOLLOWING X-IRRADIATION , 1949 .